In conjunction with the workshop, Boehringer Ingelheim Pharmaceuticals Inc., of Ridgefield, Conn., part of Boehringer Ingelheim GmbH, and Eli Lilly and Co., of Indianapolis, issued a statement supporting the American Diabetes Association's call for an independent review of the safety data of incretin-based therapies

Boehringer Ingelheim GmbH, of Ingelheim, Germany, reported new findings presented during the APASL Liver Week in Singapore, highlighting the efficacy and safety of faldaprevir(+) plus pegylated interferon and ribavirin (PegIFN/RBV) in treatment-naïve patients with genotype-1 hepatitis C virus (HCV) in Asia

Swedish Orphan Biovitrum AB, of Stockholm, Sweden, said it received approval from the FDA for the manufacture of drug substance for Kineret (anakira) at a microbial site in Vienna, Austria, owned by Boehringer Ingelheim GmbH, of Ingelheim, Germany

Boehringer Ingelheim GmbH, of Ingelheim, Germany, reported that tiotropium delivered by the Respimat SoftMist inhaler increased time to first severe exacerbation and first episode of asthma worsening across a broad spectrum of patients who remain symptomatic despite at least inhaled corticosteroid/long-acting beta2 agonist therapy

Boehringer Ingelheim GmbH, of Ingelheim, Germany, said prescribing information for Pradaxa (dabigatran etexilate), an oral anticoagulant for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation was updated

Boehringer Ingelheim GmbH, of Ingelheim, Germany, said prescribing information for Pradaxa (dabigatran etexilate), an oral anticoagulant for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation was updated

Oxford BioTherapeutics Ltd. (OBT), of Oxford, UK, and Boehringer Ingelheim GmbH, of Ingelheim, Germany, are partnering on the discovery of cancer antibody targets to be identified through OBT's OGAP discovery platform

In separate news, another Galapagos unit, Argenta, inked a deal with Boehringer Ingelheim GmbH, of Ingelheim, Germany, to apply its respiratory drug discovery services to an undisclosed target within Boehringer's respiratory disease portfolio

In separate news, another Galapagos unit, Argenta, inked a deal with Boehringer Ingelheim GmbH, of Ingelheim, Germany, to apply its respiratory drug discovery services to an undisclosed target within Boehringer's respiratory disease portfolio

Boehringer Ingelheim GmbH, of Ingelheim, Germany, is the target of a proposed national class-action lawsuit by the Toronto law firm of McPhadden Samac Tuovi LLP, relating to the blood thinner Pradax (dabigatran etexilate...Eyevensys, of Paris, received an equity investment from the Boehringer Ingelheim Venture Fund, the venture arm of Ingelheim, Germany-based Boehringer Ingelheim GmbH, and said the big pharma's head of nonclinical R&D, Michel Pairet, was appointed to its board

Boehringer Ingelheim GmbH, of Ingelheim, Germany, is the target of a proposed national class-action lawsuit by the Toronto law firm of McPhadden Samac Tuovi LLP, relating to the blood thinner Pradax (dabigatran etexilate

Boehringer Ingelheim Pharmaceuticals Inc., of Ridgefield, Conn., part of Boehringer Ingelheim GmbH, and Eli Lilly and Co., of Indianapolis, submitted a new drug application for sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin for Type II diabetes in adults

Boehringer Ingelheim Pharmaceuticals Inc., of Ridgefield, Conn., part of Boehringer Ingelheim GmbH, said a new perspective from the FDA stated the agency has not changed its recommendations regarding Pradaxa (dabigatran etexilate mesylate) capsules, following the November 2012 Mini-Sentinel evaluations

Boehringer Ingelheim GmbH, of Ingelheim, Germany, enrolled the first patient in its Phase III study (POLO-AML-2) investigating volasertib, a selective polo-like kinase inhibitor, in combination with chemotherapy in patients with acute myeloid leukemia (AML) who are ineligible for intensive therapy

Boehringer Ingelheim GmbH, of Ingelheim, Germany, said The New England Journal of Medicine published findings from the RE-MEDY and RE-SONATE trials investigating Pradaxa (dabigatran etexilate) in the long-term prevention of deep vein thrombosis or pulmonary embolism

According to Boehringer Ingelheim GmbH, of Ingelheim, Germany, tiotropium delivered once daily by Respimat inhaler improved lung function and reduced asthma exacerbations in patients who were symptomatic after treatment with inhaled corticosteroids and long-acting beta agonists (ICS/LABA) in its UniTinA-asthma Phase III trial

Boehringer Ingelheim GmbH, of Ingelheim, Germany, said the FDA's Pulmonary-Allergy Drugs Advisory Committee recommended that clinical data included in a new drug application provide substantial and convincing evidence to support the approval of olodaterol as a once-daily maintenance bronchodilator treatment for airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema

Boehringer Ingelheim GmbH, of Ingelheim, Germany, said the FDA's Pulmonary-Allergy Drugs Advisory Committee recommended that clinical data included in a new drug application provide substantial and convincing evidence to support the approval of olodaterol as a once-daily maintenance bronchodilator treatment for airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema

Boehringer Ingelheim GmbH, of Ingelheim, Germany, said its new drug application for afatinib was accepted for filing and granted priority review by the FDA...In other news, Boehringer Ingelheim said it enrolled the first patients in its Phase III interferon-free (IFN-free) program, HCVerso, testing its IFN-free polymodal regimen combining faldaprevir (BI 201335), a next-wave once-daily protease inhibitor, and BI 207127, a non-nucleoside polymerase inhibitor, plus ribavirin in hepatitis C virus